PMID- 32871809
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 34
IP  - 5
DP  - 2020 Sep-Oct
TI  - Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma.
PG  - 2745-2750
LID - 10.21873/invivo.12097 [doi]
AB  - BACKGROUND/AIM: Local recurrence in soft tissue sarcoma (STS) is a risk factor of 
      worse prognosis. Although a few studies have shown that adjuvant therapy with 
      acridine orange (AO) is effective for local control of primary STS, there have 
      been no reports examining its effectiveness for local recurrence. PATIENTS AND 
      METHODS: This retrospective study included 36 patients with first local 
      recurrence of STS. Of them, 23 patients received wide excision without AO therapy 
      (Wide group); the other 13 patients received marginal excision with AO therapy 
      (AO group). We compared re-recurrence rates between these two groups. RESULTS: 
      The total re-recurrence rate was 43.5% in the Wide group and 46.2% in the AO 
      group. There was no significant difference in local re-recurrence-free survival 
      and overall survival between the two groups. CONCLUSION: Adjuvant AO therapy 
      combined with a marginal excision suppresses local re-recurrence rates of 
      individuals with local STS recurrence.
CI  - Copyright(c) 2020, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Tsuchie, Hiroyuki
AU  - Tsuchie H
AUID- ORCID: 0000-0001-5011-7184
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan tuchikiti@yahoo.co.jp.
FAU - Emori, Makoto
AU  - Emori M
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Miyakoshi, Naohisa
AU  - Miyakoshi N
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Okada, Kyoji
AU  - Okada K
AD  - Department of Physical Therapy, Akita University Graduate School of Health 
      Sciences, Akita, Japan.
FAU - Nagasawa, Hiroyuki
AU  - Nagasawa H
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
FAU - Murahashi, Yasutaka
AU  - Murahashi Y
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Mizushima, Emi
AU  - Mizushima E
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Shimizu, Junya
AU  - Shimizu J
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Yamashita, Toshihiko
AU  - Yamashita T
AD  - Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Shimada, Yoichi
AU  - Shimada Y
AD  - Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 
      Akita, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (Antineoplastic Agents)
RN  - F30N4O6XVV (Acridine Orange)
SB  - IM
MH  - *Acridine Orange/therapeutic use
MH  - *Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Sarcoma/drug therapy
MH  - *Soft Tissue Neoplasms/drug therapy
PMC - PMC7652494
OTO - NOTNLM
OT  - Acridine orange
OT  - local recurrence
OT  - soft tissue sarcoma
COIS- This work was supported by the Japan Orthopedics and Traumatology Foundation, 
      Inc. under Grant (number: 390). Tsuchie H. reports receiving funding from a 
      research grant foundation that may be affected by the research reported in the 
      enclosed paper.
EDAT- 2020/09/03 06:00
MHDA- 2021/05/25 06:00
PMCR- 2020/09/03
CRDT- 2020/09/03 06:00
PHST- 2020/04/13 00:00 [received]
PHST- 2020/04/24 00:00 [revised]
PHST- 2020/04/27 00:00 [accepted]
PHST- 2020/09/03 06:00 [entrez]
PHST- 2020/09/03 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/09/03 00:00 [pmc-release]
AID - 34/5/2745 [pii]
AID - 10.21873/invivo.12097 [doi]
PST - ppublish
SO  - In Vivo. 2020 Sep-Oct;34(5):2745-2750. doi: 10.21873/invivo.12097.